193 related articles for article (PubMed ID: 31963430)
1. PLGA-PEG-ANG-2 Nanoparticles for Blood-Brain Barrier Crossing: Proof-of-Concept Study.
Hoyos-Ceballos GP; Ruozi B; Ottonelli I; Da Ros F; Vandelli MA; Forni F; Daini E; Vilella A; Zoli M; Tosi G; Duskey JT; López-Osorio BL
Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31963430
[TBL] [Abstract][Full Text] [Related]
2. Systemic delivery to central nervous system by engineered PLGA nanoparticles.
Cai Q; Wang L; Deng G; Liu J; Chen Q; Chen Z
Am J Transl Res; 2016; 8(2):749-64. PubMed ID: 27158367
[TBL] [Abstract][Full Text] [Related]
3. Exploiting Bacterial Pathways for BBB Crossing with PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin (CRM197): In Vivo Experiments.
Tosi G; Vilella A; Veratti P; Belletti D; Pederzoli F; Ruozi B; Vandelli MA; Zoli M; Forni F
Mol Pharm; 2015 Oct; 12(10):3672-84. PubMed ID: 26312414
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles.
Wang L; Hao Y; Li H; Zhao Y; Meng D; Li D; Shi J; Zhang H; Zhang Z; Zhang Y
J Drug Target; 2015; 23(9):832-46. PubMed ID: 25856302
[TBL] [Abstract][Full Text] [Related]
5. Angiopep-pluronic F127-conjugated superparamagnetic iron oxide nanoparticles as nanotheranostic agents for BBB targeting.
Chen GJ; Su YZ; Hsu C; Lo YL; Huang SJ; Ke JH; Kuo YC; Wang LF
J Mater Chem B; 2014 Sep; 2(34):5666-5675. PubMed ID: 32262201
[TBL] [Abstract][Full Text] [Related]
6. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
[TBL] [Abstract][Full Text] [Related]
7. The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles.
Xin H; Sha X; Jiang X; Chen L; Law K; Gu J; Chen Y; Wang X; Fang X
Biomaterials; 2012 Feb; 33(5):1673-81. PubMed ID: 22133551
[TBL] [Abstract][Full Text] [Related]
8. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.
Tosi G; Vergoni AV; Ruozi B; Bondioli L; Badiali L; Rivasi F; Costantino L; Forni F; Vandelli MA
J Control Release; 2010 Jul; 145(1):49-57. PubMed ID: 20338201
[TBL] [Abstract][Full Text] [Related]
9. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma.
Xin H; Jiang X; Gu J; Sha X; Chen L; Law K; Chen Y; Wang X; Jiang Y; Fang X
Biomaterials; 2011 Jun; 32(18):4293-305. PubMed ID: 21427009
[TBL] [Abstract][Full Text] [Related]
10. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
11. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
[TBL] [Abstract][Full Text] [Related]
12. Novel peptide-conjugated nanomedicines for brain targeting: In vivo evidence.
Duskey JT; Ottonelli I; Da Ros F; Vilella A; Zoli M; Kovachka S; Spyrakis F; Vandelli MA; Tosi G; Ruozi B
Nanomedicine; 2020 Aug; 28():102226. PubMed ID: 32479916
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.
Kirby BP; Pabari R; Chen CN; Al Baharna M; Walsh J; Ramtoola Z
J Pharm Pharmacol; 2013 Oct; 65(10):1473-81. PubMed ID: 24028614
[TBL] [Abstract][Full Text] [Related]
14. Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro.
Baysal I; Ucar G; Gultekinoglu M; Ulubayram K; Yabanoglu-Ciftci S
J Neural Transm (Vienna); 2017 Jan; 124(1):33-45. PubMed ID: 26911385
[TBL] [Abstract][Full Text] [Related]
15. PLGA Nanoparticle-Based Formulations to Cross the Blood-Brain Barrier for Drug Delivery: From R&D to cGMP.
Zhi K; Raji B; Nookala AR; Khan MM; Nguyen XH; Sakshi S; Pourmotabbed T; Yallapu MM; Kochat H; Tadrous E; Pernell S; Kumar S
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917577
[TBL] [Abstract][Full Text] [Related]
16. PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier.
Fornaguera C; Dols-Perez A; Calderó G; García-Celma MJ; Camarasa J; Solans C
J Control Release; 2015 Aug; 211():134-43. PubMed ID: 26057857
[TBL] [Abstract][Full Text] [Related]
17. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
Chen YC; Hsieh WY; Lee WF; Zeng DT
J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
[TBL] [Abstract][Full Text] [Related]
18. Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery.
Vasconcelos A; Vega E; Pérez Y; Gómara MJ; García ML; Haro I
Int J Nanomedicine; 2015; 10():609-31. PubMed ID: 25670897
[TBL] [Abstract][Full Text] [Related]
19. Escape from abluminal LRP1-mediated clearance for boosted nanoparticle brain delivery and brain metastasis treatment.
Khan NU; Ni J; Ju X; Miao T; Chen H; Han L
Acta Pharm Sin B; 2021 May; 11(5):1341-1354. PubMed ID: 34094838
[TBL] [Abstract][Full Text] [Related]
20. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
